180 Life Sciences Corp. Announces Notice of Allowance for U.S. Patent Covering Novel Method to Prevent or Reduce Post-Operative Cognitive Dysfunction
180 Life Sciences Corp. (NASDAQ:ATNF) has received a Notice of Allowance from the USPTO for a patent application covering a novel method to prevent Post-Operative Cognitive Dysfunction (POCD). The patent focuses on reducing POCD by administering anti-Human tumor necrosis factor (TNF) Alpha monoclonal antibody during surgical procedures.
POCD is a significant complication affecting elderly patients undergoing surgery, manifesting as memory loss, concentration impairment, delirium, and other cognitive issues. The company's method targets inflammatory pathways via ATNF therapy to minimize neuroinflammation post-surgery.
Notably, while this patent strengthens the company's legacy biotechnology portfolio, 180 Life Sciences is currently transitioning its focus to the global iGaming sector, developing online casino and entertainment businesses through its Technology Gaming Platform.
180 Life Sciences Corp. (NASDAQ:ATNF) ha ricevuto una Notifica di Concessione dall'USPTO per una domanda di brevetto che riguarda un nuovo metodo per prevenire la Disfunzione Cognitiva Post-Operatoria (POCD). Il brevetto si concentra sulla riduzione della POCD mediante la somministrazione di anticorpi monoclonali anti-Fattore di Necrosi Tumorale (TNF) Alfa durante gli interventi chirurgici.
La POCD è una complicanza significativa che colpisce i pazienti anziani sottoposti a interventi chirurgici, manifestandosi con perdita di memoria, difficoltà di concentrazione, delirio e altri problemi cognitivi. Il metodo dell'azienda mira a modulare le vie infiammatorie tramite la terapia ATNF per ridurre la neuroinfiammazione dopo l'operazione.
È importante sottolineare che, pur rafforzando il portafoglio biotecnologico storico dell'azienda, 180 Life Sciences sta attualmente orientando il proprio focus verso il settore globale dell'iGaming, sviluppando attività di casinò online e intrattenimento attraverso la sua Technology Gaming Platform.
180 Life Sciences Corp. (NASDAQ:ATNF) ha recibido una Notificación de Aprobación de la USPTO para una solicitud de patente que cubre un método novedoso para prevenir la Disfunción Cognitiva Postoperatoria (POCD). La patente se centra en reducir la POCD mediante la administración de anticuerpos monoclonales anti-factor de necrosis tumoral (TNF) Alfa durante procedimientos quirúrgicos.
La POCD es una complicación significativa que afecta a pacientes ancianos sometidos a cirugía, manifestándose como pérdida de memoria, dificultad para concentrarse, delirios y otros problemas cognitivos. El método de la compañía apunta a las vías inflamatorias a través de la terapia ATNF para minimizar la neuroinflamación después de la cirugía.
Cabe destacar que, aunque esta patente fortalece la cartera biotecnológica histórica de la empresa, 180 Life Sciences está actualmente cambiando su enfoque hacia el sector global de iGaming, desarrollando negocios de casinos en línea y entretenimiento mediante su Plataforma Tecnológica de Juegos.
180 Life Sciences Corp. (NASDAQ:ATNF)는 수술 후 인지장애(POCD)를 예방하는 새로운 방법에 대한 특허 출원에 대해 미국 특허청(USPTO)으로부터 허가 통지를 받았습니다. 이 특허는 수술 중에 항인간 종양괴사인자(TNF) 알파 단클론 항체를 투여하여 POCD를 감소시키는 데 중점을 두고 있습니다.
POCD는 수술을 받는 노인 환자들에게 영향을 미치는 중요한 합병증으로, 기억력 상실, 집중력 저하, 섬망 및 기타 인지 문제로 나타납니다. 회사의 방법은 ATNF 치료를 통해 염증 경로를 표적으로 하여 수술 후 신경 염증을 최소화하는 것을 목표로 합니다.
특히, 이 특허가 회사의 기존 생명공학 포트폴리오를 강화하는 한편, 180 Life Sciences는 현재 글로벌 iGaming 분야로 초점을 전환하여 기술 게임 플랫폼을 통해 온라인 카지노 및 엔터테인먼트 사업을 개발하고 있습니다.
180 Life Sciences Corp. (NASDAQ:ATNF) a reçu une Notification d'Autorisation de l'USPTO pour une demande de brevet couvrant une méthode innovante visant à prévenir la Dysfonction Cognitive Post-Opératoire (POCD). Le brevet porte sur la réduction de la POCD par l'administration d'anticorps monoclonaux anti-facteur de nécrose tumorale (TNF) Alpha humain pendant les interventions chirurgicales.
La POCD est une complication importante qui affecte les patients âgés subissant une chirurgie, se manifestant par une perte de mémoire, des troubles de la concentration, des déliriums et d'autres problèmes cognitifs. La méthode de la société cible les voies inflammatoires via la thérapie ATNF pour minimiser la neuroinflammation post-opératoire.
Il est à noter que, bien que ce brevet renforce le portefeuille biotechnologique historique de l'entreprise, 180 Life Sciences est actuellement en train de réorienter son activité vers le secteur mondial de l'iGaming, développant des entreprises de casinos en ligne et de divertissement via sa Technology Gaming Platform.
180 Life Sciences Corp. (NASDAQ:ATNF) hat eine Erteilungsmeldung vom USPTO für eine Patentanmeldung erhalten, die ein neuartiges Verfahren zur Verhinderung der Postoperativen Kognitiven Dysfunktion (POCD) abdeckt. Das Patent konzentriert sich darauf, POCD durch die Verabreichung eines anti-menschlichen Tumornekrosefaktor (TNF) Alpha monoklonalen Antikörpers während chirurgischer Eingriffe zu reduzieren.
POCD ist eine bedeutende Komplikation, die ältere Patienten nach Operationen betrifft und sich durch Gedächtnisverlust, Konzentrationsstörungen, Delirium und andere kognitive Probleme äußert. Die Methode des Unternehmens zielt darauf ab, entzündliche Signalwege mittels ATNF-Therapie zu modulieren, um die Neuroinflammation nach der Operation zu minimieren.
Bemerkenswert ist, dass dieses Patent das traditionelle Biotechnologie-Portfolio des Unternehmens stärkt, während 180 Life Sciences derzeit seinen Fokus auf den globalen iGaming-Sektor verlagert und Online-Casino- und Unterhaltungsunternehmen über seine Technology Gaming Platform entwickelt.
- Receipt of USPTO Notice of Allowance for a novel POCD treatment patent
- Patent addresses significant unmet medical need in elderly surgical patients
- Potential to enhance value of company's biotechnology portfolio
- Company is pivoting away from biotechnology to focus on iGaming sector
- Final patent issuance not yet assured
- No immediate commercialization plans mentioned for the POCD treatment
Insights
Notice of Allowance for anti-TNF therapy patent enhances legacy biotech portfolio value during company's strategic pivot to iGaming.
The USPTO's Notice of Allowance for 180 Life Sciences' patent application represents a potential addition to their intellectual property portfolio addressing an unmet medical need. Post-Operative Cognitive Dysfunction (POCD) affects a substantial proportion of elderly surgical patients, particularly following orthopedic procedures, with limited preventive options currently available.
The patent application specifically covers using anti-Human tumor necrosis factor (TNF) Alpha monoclonal antibodies administered before and during surgery to potentially reduce POCD manifestations, particularly delirium. This approach targets inflammatory pathways that may contribute to neuroinflammation following surgery—a scientifically plausible mechanism.
Several important technical considerations exist. First, this remains a Notice of Allowance rather than a granted patent, though issuance typically follows administrative procedures. Second, the press release doesn't reference clinical validation data supporting this method's efficacy. This patent would protect the method of using anti-TNF antibodies for this specific application rather than a novel compound itself.
The intellectual property has potential value in addressing POCD—a condition manifesting as memory loss, concentration impairment, delirium, and other cognitive symptoms. While 180 Life Sciences has pivoted toward iGaming, this patent development demonstrates their commitment to enhancing their legacy biotech assets, potentially creating value through future licensing or partnership opportunities in the pharmaceutical sector.
Patent progress shows dual-track strategy: enhancing biotech IP value while executing strategic pivot to iGaming entertainment.
This announcement reveals 180 Life Sciences' strategic balancing act—actively transitioning to the global iGaming sector while simultaneously extracting value from their legacy biotechnology assets. The company now explicitly identifies as "an innovative media and entertainment company" with legacy biotech IP, clearly signaling their primary strategic direction.
The patent Notice of Allowance serves dual corporate objectives: it demonstrates continued progress in their existing intellectual property portfolio while reinforcing management's commitment to maximizing shareholder value during business transformation. CEO Blair Jordan frames this development as enhancing stockholder value through their legacy assets, positioning it as complementary to their new focus.
The company appears to be following a measured transition strategy that maintains and potentially increases the value of existing biotech assets rather than abruptly abandoning their previous investments. This allows them to potentially leverage these intellectual property assets while building their new entertainment business model.
Notably, the press release provides limited details about their "Technology Gaming Platform" and specific iGaming initiatives. For investors, this announcement primarily demonstrates that management continues pursuing value from existing biotechnology assets while implementing their strategic pivot toward the entertainment sector—a hybrid approach that bridges their past investments with future direction.
PALO ALTO, CA / ACCESS Newswire / May 1, 2025 / 180 Life Sciences Corp. (NASDAQ:ATNF) ("180 Life Sciences" or the "Company"), an innovative media and entertainment company focused on the global iGaming sector, with certain legacy biotechnology intellectual property assets, today announced that the United States Patent and Trademark Office ("USPTO") has issued an official Notice of Allowance for U.S. Patent Application No. 17/556,584, covering a novel method for preventing or reducing Post-Operative Cognitive Dysfunction ("POCD").
The Notice of Allowance signifies that the USPTO has determined that the application meets all requirements for patentability. The Company notes that formal issuance of the patent is expected following completion of final administrative procedures, and cautions that a final patent grant cannot yet be assured.
POCD is a significant, often debilitating complication affecting a substantial proportion of elderly patients undergoing surgical procedures, particularly orthopedic surgeries. It can be manifested as one or more of: memory loss, memory impairment, concentration impairment, delirium, dementia, and sickness behavior. Currently, there are few effective preventive treatments available.
The newly allowed patent covers a method for reducing POCD - particularly POCD manifested as delirium - by administering an anti-Human tumor necrosis factor (TNF) Alpha ("ATNF") monoclonal antibody to the patient in a therapeutically effective amount commencing just before and during the surgical procedure. We believe that targeting inflammatory pathways via ATNF therapy represents a promising strategy for minimizing the neuroinflammation which may contribute to cognitive dysfunction following surgery.
"This Notice of Allowance highlights the underlying value of our legacy biotechnology assets and reflects the strength of intellectual property that continues to underpin 180 Life Sciences," said Blair Jordan, Chief Executive Officer of 180 Life Sciences. "As we build our future in the dynamic global iGaming sector, we remain committed to maximizing the value of our existing biotechnology portfolio. This Notice of Allowance for a US Patent demonstrates the ongoing value that our legacy IP portfolio has, and also shows that the Company is continuing to enhance this value for the benefit of all stockholders."
The Company believes that this patent if issued, will enhance the value of its biotechnology portfolio by protecting a novel therapeutic approach to an area of significant unmet medical need. At the same time, 180 Life Sciences is advancing its strategic pivot toward acquiring and developing online casino and related entertainment businesses through its proprietary Technology Gaming Platform.
About 180 Life Sciences Corp.
180 Life Sciences Corp. is an innovative biotechnology company that is currently pivoting to the global iGaming sector. The Company is dedicated to leveraging its recently acquired proprietary Technology Gaming Platform and expertise through the acquisition or development of one or more online casino and related entertainment businesses.
For more information, please visit www.180lifesciences.com.
Forward-Looking Statements
This press release includes "forward-looking statements", including information about management's view of the Company's future expectations, plans and prospects, within the safe harbor provisions provided under federal securities laws, including under The Private Securities Litigation Reform Act of 1995 (the "Act"). Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue" and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results and, consequently, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements and factors that may cause such differences include, without limitation, the Company's ability to raise funding to support its operations and commercialize its Gaming Technology Platform, the terms of such funding, and dilution caused thereby; the terms of any further financing, which may be highly dilutive and may include onerous terms; the Company's ability to commercialize its Gaming Technology Platform, and the timing and cost associated therewith; the lack of experience of current management with operating a gaming company; the ability of the Company to build out or acquire a front end for the Gaming Technology Platform, and the costs and timing associated therewith; the ability of the Company to generate revenue from the Gaming Technology Platform, including timing and cost thereof; competition in the iGaming industry; risks relating to fraud, theft or cheating; our ability to obtain and maintain licenses, and the terms thereof; our required reliance on third party cloud service providers and providers of third-party communications infrastructure, hardware and software; the review and evaluation of strategic transactions and their impact on shareholder value; the ability of the Company to maintain the continued listing of the Company's securities on The Nasdaq Stock Market; whether the patents and patent applications owned or licensed by the Company, such as the expected patent referred to in this release, will protect the Company's technology and prevent others from infringing it; whether the pending patent described herein will be granted timely or at all; our ability to monetize our legacy intellectual property assets and the timing and costs associated therewith; the Company's ability to fully comply with numerous federal, state and local laws and regulatory requirements, as well as rules and regulations outside the United States; changes in interest rates which may make borrowing more expensive and increased inflation which may negatively affect costs, expenses and returns; expectations with respect to future performance, growth and anticipated acquisitions; expectations regarding the capitalization, resources and ownership structure of the Company; the ability of the Company to execute its plans to develop and market products and the timing and costs of these programs; estimates of the size of the markets for the Company's planned products; potential future litigation involving the Company or the validity or enforceability of the intellectual property of the Company or lawsuits alleging that we have violated the intellectual property of others; global economic conditions; geopolitical events and regulatory changes; and the effect of changing interest rates and inflation, economic downturns and recessions, declines in economic activity or global conflicts.
These risk factors and others are included from time to time in documents the Company files with the Securities and Exchange Commission, including, but not limited to, its Form 10-Ks, Form 10-Qs and Form 8-Ks, and including the Annual Report on Form 10-K for the year ended December 31, 2024, and future SEC filings. These reports and filings are available at www.sec.gov and are available for download, free of charge, soon after such reports are filed with or furnished to the SEC, on the "Investors", "SEC Filings", "All SEC Filings" page of our website at www.180lifesciences.com. All subsequent written and oral forward-looking statements concerning the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, including the forward-looking statements included in this press release, which are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as otherwise provided by law.
Investor Contact:
Blair Jordan
Chief Executive Officer
Email address: bjordan@180lifesciences.com
SOURCE: 180 Life Sciences Corp.
View the original press release on ACCESS Newswire
FAQ
What is the new ATNF patent for and how does it work?
Why is 180 Life Sciences (ATNF) shifting from biotech to iGaming?
What is Post-Operative Cognitive Dysfunction (POCD) and who does it affect?
When will ATNF's POCD treatment patent be officially issued?
